| Patent Attorney's Docket No. 017753-094 IN THE DETERMINENT AND TRADEMARK OFFICE | | | | | |
|--|--|--|--|--|--|
| In re Patent Application of |) | | | | |
| Jean-Marc BALLOUL et al. |) | | | | |
| Application No.: 09/043,933 |) Group Art Unit: 1652 | | | | |
| Filed: March 30, 1998 |) Examiner: Unassigned | | | | |
| For: PHARMACEUTICAL COMPOSITION FOR TREATING PAPILLOMAVIRUS TUMORS AND INFECTION |))) | | | | |
| REPLY TRANSMITTAL LETTER | | | | | |
| Assistant Commissioner for Patents Washington, D.C. 20231 | | | | | |
| Sir: | | | | | |
| Enclosed is a reply for the above-identified pa | atent application. | | | | |
| [] A Petition for Extension of Time is also | enclosed. | | | | |
| [] Also enclosed is | • | | | | |
| | statement(s) claiming small entity status [] are also enclosed [] were submitted previously. | | | | |
| [] A Request for Entry and Consideration enclosed. | | | | | |
| [] No additional claim fee is required. | | | | | |
| [X] An additional claim fee is required, and | An additional claim fee is required, and is calculated as shown below: | | | | |

Reply Transmittal Letter Application No. <u>09/043,933</u> Attorney's Docket No. <u>017753-094</u> Page 2

| AMENDED CLAIMS | | | | | | |
|--|------------------|--|-----------------|-------------|---------------|--|
| | NO. OF CLAIMS | HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR | EXTRA CLAIMS | RATE | ADDT'L FEE | |
| Total Claims | 31 | MINUS 24 = | 7 | x \$22.00 = | 154.00 | |
| Independent Claims | 2 | MINUS 3 = | 0 | x \$82.00 = | 0.00 | |
| If Amendment adds multiple dependent claims, add \$270.00 | | | | | | |
| Total Amendment Fee | | | | | | |
| If small entity status is claimed, subtract 50% of Total Amendment Fee | | | | | 0.00 | |
| TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT 154.00 | | | | | | |

| [X] | A claim fee | in the | amount of \$_1 | .54.00 i | s enclosed. |
|-----|-------------|--------|----------------|--------------------|-------------|
| rı | Charas ¢ | | to Domonia | A a a a sum t NT a | 02 4900 |

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in triplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Bonnie D. Weiss

Registration No. 43,255

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: October 27, 1998

#5/Ple-C AR 01/19/99

Attorney's Docket No. <u>017753-094</u>

| IN THE UNITED STATES PA | TENT AND TRADEMARK OFFICE |
|---|---------------------------|
| TRADEMINE Patent Application of |) |
| Jean-Marc BALLOUL et al. |) |
| Application No.: 09/043,933 |) Examiner: Unassigned |
| Filed: March 30, 1998 |) |
| For: PHARMACEUTICAL COMPOSITI FOR TREATING PAPILLOMAVIR | • |

SUPPLEMENTAL PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

IN THE CLAIMS:

In Claim 15, kindly delete "Claim 13" and insert -- Claim 14-- in its place.

Kindly add the following claims:

25. Pharmaceutical composition according to Claim 10, wherein said early

region polypeptide is a nononcogenic variant of the E6 and/or E7 protein of a papillomavirus.

10/28/1998 AIBRAHIM 00000022 09043933

01 FC:103

154.00 OP

26. Pharmaceutical composition according to Claim 10, wherein said late region polypeptide is derived from the L1 protein, the L2 protein or from the L1 and L2 proteins.